Other strengths of the study include the strict and complete follow-up during the study (7 days a week), which ensured that patients were safe and data of good quality was retrieved, and the interim analyses that were done every 3 months by an unmasked and independent DSMB to ensure the safety of patients.The study population was not homogeneous because patients with all types of disease who were